

KEY FIGURES ON BIOSIMILAR MEDICINES



9.2 billion patient treatment days with EU approved biosimilar medicines since 2011



The number of treatment days with anti-TNF medicines **has doubled** from 2013-2023



€75 billion cumulative savings from the impact of biosimilar competition since 2007, **€13 billion** in 2024 alone



A growing opportunity for patients with over **110 new biologic medicines** opening to biosimilar competition by 2032



A considerable opportunity for European healthcare budget: a **€53.5Bn** market will open to competition by 2032



By 2030, **1st cell & gene therapies** will open to biosimilar competition



Biosimilar candidates are under development for **1/3 of biologics** losing exclusivity by 2032



Biosimilar medicines represent **5%** of the total pharmaceutical spending in Europe (~€12.6 billion)

9.2 billion
patient treatment days
with EU approved
biosimilar medicines since
2011



 biosimilar
medicines
better access. better health.

Thanks to biosimilar competition, **the number of treatment days** with anti- TNF medicines increased **x2** from 2013-2023



**€75 billion
cumulative savings**

from the impact of biosimilar
competition since 2006,

€13 billion

in 2024 alone



 biosimilar
medicines
better access. better health.

A growing opportunity
for patients with over
**110 new biologic
medicines** opening
to biosimilar
competition by 2032



A considerable opportunity
for European healthcare
budget: a **€53.5Bn**
market will **open to
competition** by 2032



By 2030,
**1st cell & gene
therapies** will open to
biosimilar competition



Biosimilar candidates
are under development for
1/3 of biologics
losing exclusivity by 2032



Biosimilar medicines
represent **5%** of the
**total pharmaceutical
spending** in Europe
(~€12.6 billion)

